IRVINE,
Calif., May 7, 2024 /CNW/ -- Seragon Biosciences,
Inc. today announced the completion of a pre-clinical study on its
novel anti-aging candidate, SRN-901. This pivotal study, conducted
in mice, was undertaken to evaluate the impact of SRN-901 on aging
as well as various health markers.
Results from the study show that SRN-901 achieved
one of the largest extensions of lifespan and healthspan to date in
the treated population. Whole-genome transcriptome sequencing was
performed on over 300 mice to assess the effects of SRN-901 at a
molecular level. The results highlighted a significant increase in
the expression of many genes associated with longevity and a
notable reduction in the expression of genes linked to aging.
Additionally, a metabolic panel revealed beneficial changes in
several biomarkers associated with younger biological age.
Other tests were conducted to evaluate the effect
of SRN-901 on healthspan, a measure of how long health is
maintained over the course of one's life. The study also evaluated
physical and cognitive function. Treadmill tests showed
significantly enhanced endurance in elderly mice. Frailty scores
showed marked improvement in the elderly mice receiving SRN-901,
and there was a significant reduction in tumor occurrence in the
treated group.
The research team at Seragon Biosciences is
encouraged by the study's results and will conduct further analysis
to uncover additional findings. These results will be published
once the supplementary analysis is complete.
About Seragon Biosciences
Seragon Biosciences, Inc., headquartered in
Irvine, California, is a
research-based biopharmaceutical company dedicated to improving
human and animal health through innovative science. Seragon
Biosciences is committed to applying cutting-edge scientific and
technological advancements to the fields of aging, metabolism, gene
therapy, and bioinformatics. From the research end to consumer
products and clinical applications, Seragon strives to bring people
access to the most significant breakthroughs in medicine. For more
information, please visit www.seragon.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/seragon-completes-pre-clinical-study-of-aging-intervention-candidate-srn-901-302137573.html
SOURCE Seragon Biosciences